 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || ACM-001 / ACM Biolabs
Review, Journal: Amphiphilic Block Copolymer Nanostructures as a Tunable Delivery Platform: Perspective and Framework for the Future Drug Product Development. (Pubmed Central) - Jan 19, 2024
However, several limitations need to be resolved before they can reach their full potential. In this Perspective, we would like to highlight such aspects requiring further development for translating an ABCP-based delivery platform from a proof of concept to a viable commercial product.
- || ACM-001 / ACM Biolabs
Trial completion, Trial completion date: Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally. (clinicaltrials.gov) - Oct 24, 2023
P1, N=38, Completed, Sponsor: ACM Biolabs
In this Perspective, we would like to highlight such aspects requiring further development for translating an ABCP-based delivery platform from a proof of concept to a viable commercial product. Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Aug 2023
- || ACM-001 / ACM Biolabs
Enrollment closed, Enrollment change, Trial primary completion date: Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally. (clinicaltrials.gov) - Jul 6, 2023
P1, N=38, Active, not recruiting, Sponsor: ACM Biolabs
Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Aug 2023 Recruiting --> Active, not recruiting | N=80 --> 38 | Trial primary completion date: Dec 2022 --> Jun 2023
- ||| ACM-001 / ACM Biolabs
Enrollment open: Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally. (clinicaltrials.gov) - Jul 20, 2022
P1, N=80, Recruiting, Sponsor: ACM Biolabs
Recruiting --> Active, not recruiting | N=80 --> 38 | Trial primary completion date: Dec 2022 --> Jun 2023 Not yet recruiting --> Recruiting
- | ACM-001 / ACM Biolabs
New P1 trial: Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally. (clinicaltrials.gov) - May 23, 2022
P1, N=80, Not yet recruiting, Sponsor: ACM Biolabs